title: PharmGKB summary: gemcitabine pathway.
authors.affiliation: Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cDepartment of Pharmacotherapy and Translational Research dCenter for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida eDepartment of Molecular Pharmacology & Experimental Therapeutics, Division of Clinical Pharmacology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Maria L
authors.initials: ML
authors.lastname: Alvarellos
authors.forename: Jatinder
authors.initials: J
authors.lastname: Lamba
authors.forename: Katrin
authors.initials: K
authors.lastname: Sangkuhl
authors.forename: Caroline F
authors.initials: CF
authors.lastname: Thorn
authors.forename: Liewei
authors.initials: L
authors.lastname: Wang
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Klein
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics / Q000494:pharmacology*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D010597:Pharmacogenetics; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine